Skip to main content
In AS (n=91,493), D2T defined as ≥2 b/tsDMARD classes plus elevated CRP. Risk factors: HLA-B27+ (OR 1.30), obesity (OR

Antoni Chan MD (Prof) synovialjoints

1 year 1 month ago
In AS (n=91,493), D2T defined as ≥2 b/tsDMARD classes plus elevated CRP. Risk factors: HLA-B27+ (OR 1.30), obesity (OR 1.20), depression (OR 1.22). D2T group had higher CRP (55.7 mg/L), BMI (31.1), and more EAMs (IBD, psoriasis, uveitis). Female predominance (56.9%)Abstract https://t.co/EHCt5wq4ot
#EULAR2025 Abstr#OP0199 Validation of effective & safe HCQ blood levels monitoring (750-1150ng/mL) to guide optimal

Md Yuzaiful Md Yusof Yuz6Yusof

1 year 1 month ago
#EULAR2025 Abstr#OP0199 Validation of effective & safe HCQ blood levels monitoring (750-1150ng/mL) to guide optimal dose. Particulary important in those with CKD Stage =>3 as considered high risk of toxicity. Next steps: wider availability & cost-effectiveness analysis @RheumNow https://t.co/WoVFolrmPA
#EULAR2025 Abstr#OP0200 Which social determinant of health in Europe affect #SLE outcomes so that these can be improved?

Md Yuzaiful Md Yusof Yuz6Yusof

1 year 1 month ago
#EULAR2025 Abstr#OP0200 Which social determinant of health in Europe affect #SLE outcomes so that these can be improved? Registry in Sweden showed factors associated with damage/mortality: - Lower income & education, - No partner - On sick leave/disability benefits @RheumNow https://t.co/hgEfJzoqNg
#EULAR2025 Abstr#OP0201 Achieving treatment targets (LLDAS and/or DORIS) is more prognostically important. In Phase 3 RC

Md Yuzaiful Md Yusof Yuz6Yusof

1 year 1 month ago
#EULAR2025 Abstr#OP0201 Achieving treatment targets (LLDAS and/or DORIS) is more prognostically important. In Phase 3 RCT, compared with PBO+SOC, Dapirolizumab+SOC resulted in higher rates of achievement and time in LLDAS and DORIS. LLDAS plateud after WK28 in PBO+SOC @RheumNow https://t.co/3Zd3jjx984
#EULAR2025 Abstr#OP0198 Long-term extension study of Phase 2 #SLE showed efficacy of Upadacitinib and UPA + Elsubrutinib

Md Yuzaiful Md Yusof Yuz6Yusof

1 year 1 month ago
#EULAR2025 Abstr#OP0198 Long-term extension study of Phase 2 #SLE showed efficacy of Upadacitinib and UPA + Elsubrutinib were maintained through to Week 104. Those who switched from PBO at WK48 to UPA + ELSU also improved. No VTE or MACE. Is add-on ELSU really needed? @RheumNow https://t.co/x8NbAtsHh0
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. A

Dr. John Cush RheumNow

1 year 1 month ago
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty.
Live Daily Eular 2025 Recap Day 1 https://t.co/dLV83VcGuC

Dr. John Cush RheumNow

1 year 1 month ago
Live Daily Eular 2025 Recap Day 1 https://t.co/dLV83VcGuC
Worth mentioning: the type of monoclonal protein is important for diagnosis. Different diseases with different therapies

David Liew drdavidliew

1 year 1 month ago
Worth mentioning: the type of monoclonal protein is important for diagnosis. Different diseases with different therapies #EULAR2025 @RheumNow l https://t.co/5bbQnHV6CI
#neuromodulation in #rheumatoid #arthritis

What is it?
👇
Autonomic & immune system interaction

Who seeks thi

Janet Pope Janetbirdope

1 year 1 month ago
#neuromodulation in #rheumatoid #arthritis What is it? 👇 Autonomic & immune system interaction Who seeks this Rx? desperate pts w pain No Rx left Interested in technology #EULAR2025 @RheumNow @eular_org #D2T #RA https://t.co/XWWFiUK6Em
#vagal & #splenic #nerves most studied
In #immune #system interaction

#PNS can detect #inflammation

use in #D2T #

Janet Pope Janetbirdope

1 year 1 month ago
#vagal & #splenic #nerves most studied In #immune #system interaction #PNS can detect #inflammation use in #D2T #RA w active disease ? Key factors in #neurostimulation - many #EULAR2025 @RheumNow @eular_org #D2T in #RA session https://t.co/tCgpGtI5z2
The great debate: are cannabis and cannabinoids a valid treatment option in patients with rheumatic diseases?

A thread

Aurelie Najm AurelieRheumo

1 year 1 month ago
The great debate: are cannabis and cannabinoids a valid treatment option in patients with rheumatic diseases? A thread 🧵👇🏼 @RheumNow #EULAR2025 https://t.co/KLZN9MvcFy
Interesting debate today #EULAR2025 about medical cannabis - where relative harms have come up.

Would you rather be add

David Liew drdavidliew

1 year 1 month ago
Interesting debate today #EULAR2025 about medical cannabis - where relative harms have come up. Would you rather be addicted to prescription opioids or recreational cannabis? (not going to argue about cannabis addiction - let’s say social impact is equal) @RheumNow
#Vagal #nerve #stimulation
Hand held device
#BDMARD failure
Plausible - improved pro inflammatory cytokines

wears off

Janet Pope Janetbirdope

1 year 1 month ago
#Vagal #nerve #stimulation Hand held device #BDMARD failure Plausible - improved pro inflammatory cytokines wears off benefit if stopped Attenuates in ~half over yrs Open label uncontrolled @RheumNow @eular_org #EULAR2025 Session D2T-RA https://t.co/98K5gwasHv
#RCT of #vagus #nerve #stimulation in #bDMARD-IR #RA Pts

RESSET RCT
+RA #RCT w #VNS

But low response with stat signif

Janet Pope Janetbirdope

1 year 1 month ago
#RCT of #vagus #nerve #stimulation in #bDMARD-IR #RA Pts RESSET RCT +RA #RCT w #VNS But low response with stat significance ACR20 1/4 sham vs 1/3 VNS Would add on to new SoC? 🤔 #EULAR2025 @RheumNow #eular_org #D2T- RA-session https://t.co/tR1pLPBr74
×